- Home
- CELU vs MRSN Comparison
CELU vs MRSN Comparison
Compare CELU & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELU
- MRSN
- Stock Information
- Founded
- CELU 2016
- MRSN 2001
- Country
- CELU United States
- MRSN United States
- Employees
- CELU N/A
- MRSN N/A
- Industry
- CELU Biotechnology: Pharmaceutical Preparations
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- CELU Health Care
- MRSN Health Care
- Exchange
- CELU Nasdaq
- MRSN Nasdaq
- Market Cap
- CELU 42.2M
- MRSN 40.7M
- IPO Year
- CELU N/A
- MRSN 2017
- Fundamental
- Price
- CELU $3.03
- MRSN $0.35
- Analyst Decision
- CELU
- MRSN Strong Buy
- Analyst Count
- CELU 0
- MRSN 5
- Target Price
- CELU N/A
- MRSN $5.75
- AVG Volume (30 Days)
- CELU 491.2K
- MRSN 3.1M
- Earning Date
- CELU 05-08-2025
- MRSN 08-12-2025
- Dividend Yield
- CELU N/A
- MRSN N/A
- EPS Growth
- CELU N/A
- MRSN N/A
- EPS
- CELU N/A
- MRSN N/A
- Revenue
- CELU $54,220,000.00
- MRSN $34,006,000.00
- Revenue This Year
- CELU $23.29
- MRSN N/A
- Revenue Next Year
- CELU N/A
- MRSN $1.03
- P/E Ratio
- CELU N/A
- MRSN N/A
- Revenue Growth
- CELU 138.11
- MRSN N/A
- 52 Week Low
- CELU $1.00
- MRSN $0.26
- 52 Week High
- CELU $5.22
- MRSN $2.83
- Technical
- Relative Strength Index (RSI)
- CELU 71.05
- MRSN 52.71
- Support Level
- CELU $2.01
- MRSN $0.32
- Resistance Level
- CELU $2.66
- MRSN $0.38
- Average True Range (ATR)
- CELU 0.24
- MRSN 0.03
- MACD
- CELU 0.08
- MRSN 0.01
- Stochastic Oscillator
- CELU 91.67
- MRSN 69.00
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.